Seattle Genetics' armed antibody scores high in frontline bladder cancer, taking center stage at ESMO
BARCELONA — Seattle Genetics and Astellas are off to a strong start in expanding their franchise for the armed antibody enfortumab vedotin — before it’s actually on the market.
Now under review at the FDA after hitting its marks for second-line advanced bladder cancer for patients who had failed chemo or a PD-1(L)1 checkpoint, researchers for the two companies turned up at ESMO to show off how their drug combined with Keytruda triggered an impressive 71% overall response rate in frontline patients — 32 of 45 patients — who were ineligible for chemo. There was a 13% complete response rate and the large majority of the responses — 91% — were visible at the first assessment.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.